Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Identifying surrogate markers for survival in MM

David Siegel • 13 Sep 2019
IMW 2019
Multiple Myeloma

David Siegel, MD, PhD, John Theurer Cancer Center, Hackensack, NJ, discusses the evergrowing need to identify novel surrogate markers for survival, including MRD and other endpoints, such as time to MRD negativity relapse, among others presented at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from David Siegel

10:09
Does maintenance therapy increase overall survival in myeloma?
Andrew Spencer et al. • 13 Sep 2019
12:34
Transplantation in modern myeloma therapeutics
Andrew Spencer et al. • 13 Sep 2019
5:24
The role of transplantation in the treatment of multiple myeloma
David Siegel • 13 Sep 2019
9:28
CAR T-cells in myeloma: exploratory targets & payment models
Andrew Spencer et al. • 7 Sep 2018

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals